These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37745058)

  • 1. Corrigendum: Mitigation of acetaminophen-induced liver toxicity by the novel phosphatidylinositol 3-kinase inhibitor alpelisib.
    Shaker ME; Gomaa HAM; Hazem SH; Abdelgawad MA; El-Mesery M; Shaaban AA
    Front Pharmacol; 2023; 14():1281416. PubMed ID: 37745058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitigation of acetaminophen-induced liver toxicity by the novel phosphatidylinositol 3-kinase inhibitor alpelisib.
    Shaker ME; Gomaa HAM; Hazem SH; Abdelgawad MA; El-Mesery M; Shaaban AA
    Front Pharmacol; 2023; 14():1212771. PubMed ID: 37608890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DAMPs and sterile inflammation in drug hepatotoxicity.
    Yang R; Tonnesseen TI
    Hepatol Int; 2019 Jan; 13(1):42-50. PubMed ID: 30474802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Corrigendum: Advances in the study of acetaminophen-induced liver injury.
    Li X; Ni J; Chen L
    Front Pharmacol; 2023; 14():1283596. PubMed ID: 37808184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corrigendum: Inflammatory Stress Potentiates Emodin-Induced Liver Injury in Rats.
    Tu C; Gao D; Li XF; Li CY; Li RS; Zhao YL; Li N; Jia GL; Pang JY; Cui HR; Ma ZJ; Xiao XH; Wang JB
    Front Pharmacol; 2020; 11():597772. PubMed ID: 33568998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A sensitive HPLC-FLD method for the quantification of alpelisib, a novel phosphatidylinositol 3-kinase inhibitor, in rat plasma: Drug metabolism and pharmacokinetic evaluation in vitro and in vivo.
    Seo SW; Kim JM; Han DG; Geum D; Yun H; Yoon IS
    J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Jan; 1163():122508. PubMed ID: 33387858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Periorbital edema associated with alpelisib.
    Dao EA; George SJ; Heberton MM; Pacha O; Kovitz CA; Patel AB; Phillips RM
    Cancer Treat Res Commun; 2022; 32():100596. PubMed ID: 35834907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpelisib combination treatment as novel targeted therapy against hepatocellular carcinoma.
    Xu H; Chen K; Shang R; Chen X; Zhang Y; Song X; Evert M; Zhong S; Li B; Calvisi DF; Chen X
    Cell Death Dis; 2021 Oct; 12(10):920. PubMed ID: 34625531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic therapeutic potential of alpelisib in cancers (excluding breast cancer): Preclinical and clinical evidences.
    Ye Y; Huang Z; Zhang M; Li J; Zhang Y; Lou C
    Biomed Pharmacother; 2023 Mar; 159():114183. PubMed ID: 36641927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of tumor necrosis factor receptor 1 (p55) in hepatocyte proliferation during acetaminophen-induced toxicity in mice.
    Chiu H; Gardner CR; Dambach DM; Durham SK; Brittingham JA; Laskin JD; Laskin DL
    Toxicol Appl Pharmacol; 2003 Dec; 193(2):218-27. PubMed ID: 14644624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer.
    Rugo HS; André F; Yamashita T; Cerda H; Toledano I; Stemmer SM; Jurado JC; Juric D; Mayer I; Ciruelos EM; Iwata H; Conte P; Campone M; Wilke C; Mills D; Lteif A; Miller M; Gaudenzi F; Loibl S
    Ann Oncol; 2020 Aug; 31(8):1001-1010. PubMed ID: 32416251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpelisib-Induced Diabetic Ketoacidosis in a Non-diabetic Patient.
    Fugere T; Roy AM; Makhoul I
    Cureus; 2021 Nov; 13(11):e19295. PubMed ID: 34900474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Highly expressed protein kinase A inhibitor α and suppression of protein kinase A may potentiate acetaminophen-induced hepatotoxicity.
    Yun JW; Kim M; Cho SD; Lee JY; Bae ON; Lim KM
    Toxicol Lett; 2014 Aug; 229(1):59-65. PubMed ID: 24910983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies.
    Tsang ES; Aggarwal RR; Dhawan MS; Bergsland EK; Alvarez EA; Calabrese S; Pacaud R; Garcia J; Fattah D; Thomas S; Grabowsky J; Moasser MM; Munster PN
    Cancer Res Commun; 2022 Jul; 2(7):570-576. PubMed ID: 36923283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.
    Juric D; Rodon J; Tabernero J; Janku F; Burris HA; Schellens JHM; Middleton MR; Berlin J; Schuler M; Gil-Martin M; Rugo HS; Seggewiss-Bernhardt R; Huang A; Bootle D; Demanse D; Blumenstein L; Coughlin C; Quadt C; Baselga J
    J Clin Oncol; 2018 May; 36(13):1291-1299. PubMed ID: 29401002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P110α inhibitor alpelisib exhibits a synergistic effect with pyrotinib and reverses pyrotinib resistant in HER2+ breast cancer.
    Chen H; Si Y; Wen J; Hu C; Xia E; Wang Y; Wang O
    Neoplasia; 2023 Sep; 43():100913. PubMed ID: 37348428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer.
    Tankova T; Senkus E; Beloyartseva M; Borštnar S; Catrinoiu D; Frolova M; Hegmane A; Janež A; Krnić M; Lengyel Z; Marcou Y; Mazilu L; Mrinakova B; Percik R; Petrakova K; Rubovszky G; Tokar M; Vrdoljak E
    Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corrigendum: Adenosine kinase on deoxyribonucleic acid methylation: Adenosine receptor-independent pathway in cancer therapy.
    Luo HY; Shen HY; Perkins RS; Wang YX
    Front Pharmacol; 2023; 14():1200491. PubMed ID: 37124214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corrigendum: Polypharmacy to Mitigate Acute and Delayed Radiation Syndromes.
    Gasperetti T; Miller T; Gao F; Narayanan J; Jacobs ER; Szabo A; Cox GN; Orschell CM; Fish BL; Medhora M
    Front Pharmacol; 2021; 12():741485. PubMed ID: 34512365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1.
    André F; Ciruelos EM; Juric D; Loibl S; Campone M; Mayer IA; Rubovszky G; Yamashita T; Kaufman B; Lu YS; Inoue K; Pápai Z; Takahashi M; Ghaznawi F; Mills D; Kaper M; Miller M; Conte PF; Iwata H; Rugo HS
    Ann Oncol; 2021 Feb; 32(2):208-217. PubMed ID: 33246021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.